Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Tmunity Therapeutics

Tmunity Therapeutics

Tmunity Therapeutics is a biotechnology company developing t-cell immunotherapies for the treatment of human diseases.

Tmunity Therapeutics is a biotechnology company developing t-cell immunotherapies for the treatment of human diseases that is headquartered in Philadelphia, Pennsylvania. It was founded in 2015 by Carl June, Bruce Levine, Yangbing Zhao, Anne Chew, James Riley, and Bruce Blazar.

Product

The company conducts research and development around the aforementioned field of study. It uses laboratory and production facilities at the University of Pennsylvania, as well as its own production facility located near the city. It has multiple novel therapies, many of which are in the pre-clinical and clinical stages of development.

Timeline

October 31, 2029
Tmunity Therapeutics raises a $75,000,000 series B round.
November 2019
Tmunity Therapeutics raises a $75,000,000 series B round from Andreessen Horowitz, Be The Match BioTherapies, Gilead Sciences and Westlake Village BioPartners.
October 2019
Tmunity Therapeutics raises a $74,999,948 series B round from American Cancer Society, Andreessen Horowitz, Be The Match, Be The Match BioTherapies, Gilead Sciences, The a16z Cultural Leadership Fund, University of Pennsylvania and Westlake Village BioPartners.
January 23, 2018
Tmunity Therapeutics raises a $100,000,000 series A round.
January 23, 2018
Tmunity Therapeutics raises a $100,000,000 series A round from Be The Match BioTherapies, Gilead Sciences and Lilly Asia Ventures.
2015
Tmunity Therapeutics was founded by Dr. Anne Chew, Dr. Bruce Levine, Dr. Carl H. June, Dr. James L. Riley and Dr. Yangbing Zhao.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Tmunity Therapeutics

April 27, 2018

Tmunity Therapeutics Raises $100 Million in Series A Financing to Advance Portfolio of Next-Generation T cell Immunotherapies to Transform the Treatment of Cancer

Business Wire

Web

Tmunity Therapeutics, Inc. to Advance IND-Enabling Activities for Personalized Next-Generation Engineered T Cell Therapies with $10 Million Financing

Tmunity Therapeutics

Web

News

Title
Author
Date
Publisher
Description
Nick Paul
June 3, 2021
FierceBiotech
Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which were first reported by Endpoints, has implications for the broader push to establish cell therapies as treatments for solid tumors.
Amirah Al Idrus
February 9, 2021
FierceBiotech
Tmunity Therapeutics was born out of an extensive collaboration with the University of Pennsylvania that netted it the technology, know-how and programs it needed to go after better cell therapies for cancer. Now, the biotech is bolstering that pact, picking up a new CAR-T program and the rights to certain technologies.

References

Golden logo
By using this site, you agree to our Terms & Conditions.